Todd Harris - Sep 17, 2021 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role: Chief Executive Officer, Director
Signature: /s/ John Healy, Attorney-in Fact
Stock symbol: TYRA
Transactions as of: Sep 17, 2021
Transactions value $: $0
Form type: 4
Date filed: 9/17/2021, 04:43 PM
Previous filing: Sep 14, 2021
Next filing: Nov 4, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TYRA	Common Stock	Conversion of derivative security		+34K	+2.05%		1.7M	Sep 17, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TYRA	Series A Preferred Stock	Conversion of derivative security	$0	-13.1K	-100%	$0.00^*	0	Sep 17, 2021	Common Stock	34K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.